CRRT联合乌司他丁对急性感染性休克患者炎症状态及肾功能的影响

doi:10.3969/j.issn.1001-8131.2022.02.011

Abstract
Figure/Table
References
Related Citation (8)

Download: PDF (462 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the effect of continuous renal replacement therapy（CRRT）combined with ulinastatin on inflammatory state and renal function in patients with acute septic shock.Methods Retrospective analysis,50 cases of acute septic shock patients were selected as the control group（CRRT treatment）,and 48 cases of acute septic shock patients were selected as the observation group（CRRT combined with ulinastatin treatment）.The inflammatory status and renal function were compared between the two groups before and after treatment for 3 days.Results After 3 days of treatment,white blood cell count（WBC）,C-reactive protein（CRP）,procalcitonin（PCT）in the two groups were compared The levels of interleukin-6（IL-6）,interleukin-10（IL-10）,tumor necrosis factor（TNF - α）in the observation group were lower than those in the control group,and the difference was statistically significant（P<0.05）;after 3 days of treatment,the levels of bun and SCR in the two groups were lower than those before treatment,and the levels of the above indexes in the observation group were lower than those in the control group（P<0.05）. Conclusion CRRT combined with ulinastatin can effectively remove inflammatory substances and improve renal function in patients with acute septic shock,which has high clinical application value.

Key words： Acute septic shock Continuous renal replacement therapy Ulinastatin Inflammatory state Renal function

Received: 02 February 2021

PACS:

R457.2

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Qian Qing

Cite this article:

Qian Qing. Effect of CRRT combined with Ulinastatin on inflammatory state and renal function in patients with acute septic shock[J]. journal1, 2022, 42(2): 29-30.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2022.02.011 OR http://www.hrbyybjb.org.cn/EN/Y2022/V42/I2/29

[1] 王磊. 不同CRRT治疗剂量对感染性休克患者临床疗效、应激反应及细胞免疫功能的影响[J].山东医药,2018,58(18):85-87.
[2] 王咸安,陈梁,王玉花.生脉注射液联合乌司他丁治疗感染性休克的临床研究[J].现代药物与临床,2017,32(2):249-252.
[3] 中国医师协会急诊医师分会,中国研究型医院学会休克与脓毒症专业委员会.中国脓毒症/脓毒性休克急诊治疗指南(2018)[J].中国急救医学,2018,38(9):741-756.
[4] 孟祥忠,卫峰,王娜,等.65例脓毒性休克患者血浆降钙素原及C反应蛋白水平的临床分析[J].实用临床医药杂志,2018,22(3):120-122.
[5] 罗钰,曹权.炎症因子在老年脓毒性休克早期的改变及对预后的评估价值[J].中国实验诊断学,2017,21(11):1912-1914.
[6] 张娟,黄智勇,谢荣裕,等.连续肾脏替代疗法血液净化在重症监护室感染性休克患者中的应用效果研究[J].中国医学装备,2018,15(11):116-118.
[7] 亢宏山,白艳,刘淑红,等.乌司他丁联合CRRT在ICU感染性休克患者应用效果评价[J].中国急救复苏与灾害医学杂志,2016,11(11):1079-1083.
[8] 丁国雷,练睿,袁烁.连续性肾脏替代治疗时机对脓毒性休克伴急性肾损伤患者预后的影响[J].中日友好医院学报,2019,33(6):346-348.
[9] 米芷颉,龚鸿昌,俸小飞.连续肾脏替代疗法对感染性休克致急性肾损伤患者的临床意义[J].标记免疫分析与临床,2018,25(7):1048-1051,1056.
[10] Putzu A,Fang M X,Boscolo Berto M,et al.Blood purification with continuous veno-venous hemofiltration in patients with sepsis or ARDS:a systematic review and meta-analysis[J].Minerva Anestesiologica,2017,83(8):867-877.
[11] 卢运生,文晓宏,吉雪芳,等.乌司他丁联合血必净注射液治疗脓毒性休克的疗效观察[J].实用临床医药杂志,2017,21(9):189-190.
[12] 王咸安,陈梁,王玉花.生脉注射液联合乌司他丁治疗感染性休克的临床研究[J].现代药物与临床,2017,32(2):249-252.
[13] 熊敏君,吕光宇,王晓源,等.氢化可的松联合乌司他丁治疗脓毒性休克的效果[J].中国医药导报,2019,16(32):111-114.
[14] 虎琼华,周瑜,张鸣,等.乌司他丁联合持续性肾脏替代疗法治疗感染性休克临床效果观察[J].临床误诊误治,2018,31(2):56-62.
[15] Jiang W,Yu X,Sun T,et al.ADJunctive Ulinastatin in Sepsis Treatment in China(ADJUST study):study protocol for a randomized controlled trial[J].Trials,2018,19(1):133.